|
🐜
|
Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study.
8 auth.
F. Gaalen,
S. Linn-Rasker,
W. Venrooij,
B. D. Jong,
F. Breedveld,
C. Verweij,
...
R. Toes,
T. Huizinga
|
9 |
2004 |
9
🐜
|
|
🐜
|
Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review.
8 auth.
B. D. Lange-Brokaar,
A. Ioan-Facsinay,
G. Osch,
A. Zuurmond,
J. Schoones,
R. Toes,
...
T. Huizinga,
M. Kloppenburg
|
9 |
2012 |
9
🐜
|
|
🐜
|
Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial.
13 auth.
H. van Dongen,
J. van Aken,
L. R. Lard,
K. Visser,
H. K. Ronday,
H. Hulsmans,
I. Speyer,
M. Westedt,
A. Peeters,
C. Allaart,
...
R. Toes,
F. C. Breedveld,
Tom W. J. Huizinga
|
8 |
2007 |
8
🐜
|
|
🐜
|
Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles
9 auth.
S. Linn-Rasker,
A. H. Mil,
F. Gaalen,
M. Kloppenburg,
R. D. Vries,
S. Cessie,
...
F. Breedveld,
R. Toes,
T. Huizinga
|
8 |
2005 |
8
🐜
|
|
🐢
|
Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways.
8 auth.
L. Trouw,
E. M. Haisma,
E. Levarht,
D. Woude,
A. Ioan-Facsinay,
M. Daha,
...
T. Huizinga,
R. Toes
|
7 |
2009 |
7
🐢
|
|
🐢
|
Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response.
9 auth.
K. N. Verpoort,
C. M. J. Zijde,
E. Voort,
A. Ioan-Facsinay,
J. W. Drijfhout,
M. V. Tol,
...
F. Breedveld,
T. Huizinga,
R. Toes
|
7 |
2006 |
7
🐢
|
|
🐜
|
Antibodies to Porphyromonas gingivalis Are Associated with Anticitrullinated Protein Antibodies in Patients with Rheumatoid Arthritis and Their Relatives
13 auth.
C. Hitchon,
F. Chandad,
E. Ferucci,
A. Willemze,
A. Ioan-Facsinay,
D. van der Woude,
J. Markland,
D. Robinson,
B. Elias,
M. Newkirk,
...
R. Toes,
T. Huizinga,
H. El-Gabalawy
|
7 |
2010 |
7
🐜
|
|
🐜
|
Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
8 auth.
D. van der Woude,
A. Young,
K. Jayakumar,
B. Mertens,
R. Toes,
D. M. van der Heijde,
...
T. Huizinga,
A. H. M. van der Helm-van Mil
|
7 |
2009 |
7
🐜
|
|
🐜
|
Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis.
7 auth.
Jing Shi,
L. A. van de Stadt,
E. Levarht,
T. Huizinga,
R. Toes,
L. Trouw,
...
D. van Schaardenburg
|
7 |
2013 |
7
🐜
|
|
🐜
|
Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
7 auth.
Y. Teng,
E. Levarht,
M. Hashemi,
I. Bajema,
R. Toes,
T. Huizinga,
...
J. V. van Laar
|
7 |
2007 |
7
🐜
|
|
🐜
|
Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
8 auth.
M. V. D. van der Linden,
D. van der Woude,
A. Ioan-Facsinay,
E. Levarht,
G. Stoeken-Rijsbergen,
T. Huizinga,
...
R. Toes,
A. H. M. van der Helm-van Mil
|
7 |
2009 |
7
🐜
|
